400 likes | 777 Views
Chapter 5: Growth Factors, Receptors, and Cancer. Spatial and temporal control of cell growth and differentiation via communication between individual cells are pivotal for maintaining functional and structural integrity of tissues and organs. e.g. Wound healing.
E N D
Chapter 5: Growth Factors, Receptors, and Cancer
Spatial and temporal control of cell growth and differentiation via communication between individual cells are pivotal for maintaining functional and structural integrity of tissues and organs
Effect of growth factors on cell proliferation and migration
Experimental clues for cell-to-cell signaling via growth factors from studies for the tyrosine kinase activity of v-Src
Pleiotropic actions and substrate specificity of protein kinases
Alterations in structures and expression of RTKs make them function as oncogenes
Transphosphorylation underlies the operation of RTKs Human A431 epidermoid carcinoma cells
Alternative mechanisms of growth factor-induced receptor dimerization
[2] Cytokine receptor noncovalently interacting with tyrosine kinases
[4] Notch receptor of which activation depends on proteolytic cleavage
[6] Non-canonical Wnt signalingvia frizzled receptors: G-protein-coupled receptor (GPCR)
[8] Receptors sensing association between the cell and the extracellular matrix (ECM)
Suppressed mammary tumorigenesis in the absence of b1 integrin
EGFR overexpression: Colorectal cancer (22-77%) Pancreatic cancer (30-50%) Lung cancer (40-80%) Non-small cell lung cancer (14-91%) Ras mutation: Papillary thyroid cancer (90%) Pancreatic cancer (60%) Colon cancer (50%) Non-small cell lung cancer (30%) SOS Ras* EGFR* EGFR* Grb2 Imatinib Farnesyl transferase B-raf mutation: Melanoma (70%) Papillary thyroid cancer (50%) Colon cancer (10%) Raf* SB590885 PLX4720 XL281 RAF256 Sorafenib PLX4032 EGFR mutaion: NSCLC (10%) Glioblastoma (20%) MEK XL518 CI-1040 PD035091 AZD6244 GSK1120212 ERK1/2 Myc RSK Elk-1 Transcription Translation Survival / Proliferation / Suppression of apoptosis Ras/Raf/MAPK signaling cascade activated in human cancers and anti-cancer drugs, targeting the pathway, currently in development. Asterisk indicates mutations found in human cancers.